The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, Ismail-Beigi F, Dadashi M, Ghanbari S, Taheri H, Fathi M, Muhammadi MJ, Mahmoodian R, Asgari A, Tayaranian M, Moharrami M, Mahjani M, Ghobadian B, Chiti H, Gohari S.
Gohari S, et al. Among authors: dadashi m.
Diabetol Metab Syndr. 2022 Nov 17;14(1):170. doi: 10.1186/s13098-022-00951-5.
Diabetol Metab Syndr. 2022.
PMID: 36397128
Free PMC article.